ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,78
0,22%
Bitcoin
66 348,05
0,11%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Monte Rosa Therapeutics Inc (GLUE)

  7. Monte Rosa Therapeutics Inc (GLUE) Actualités

GLUE

Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GLUE
DateHeureSourceTitreSymboleSociété
16/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
16/05/202422h04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
16/05/202413h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public OfferingNASDAQ:GLUEMonte Rosa Therapeutics Inc
15/05/202422h01GlobeNewswire Inc.Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:GLUEMonte Rosa Therapeutics Inc
09/05/202413h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
09/05/202413h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
02/05/202422h01GlobeNewswire Inc.Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerNASDAQ:GLUEMonte Rosa Therapeutics Inc
14/03/202412h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
11/03/202412h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway InhibitorNASDAQ:GLUEMonte Rosa Therapeutics Inc
31/01/202413h00GlobeNewswire Inc.Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
08/01/202413h15GlobeNewswire Inc.Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024NASDAQ:GLUEMonte Rosa Therapeutics Inc
04/01/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
03/01/202413h00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
21/11/202313h00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
09/11/202313h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
07/11/202316h00GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
26/10/202322h30GlobeNewswire Inc.Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq RulesNASDAQ:GLUEMonte Rosa Therapeutics Inc
17/10/202313h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid TumorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
17/10/202313h00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
18/08/202322h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
15/08/202323h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
10/08/202313h15GlobeNewswire Inc.Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
26/07/202313h30GlobeNewswire Inc.Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of DirectorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
15/06/202322h43Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GLUEMonte Rosa Therapeutics Inc
14/06/202322h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GLUEMonte Rosa Therapeutics Inc
30/05/202322h30GlobeNewswire Inc.Monte Rosa Therapeutics to Present at Upcoming Investor and Industry ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
23/05/202313h30GlobeNewswire Inc.Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
11/05/202313h30GlobeNewswire Inc.Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
26/04/202322h09Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:GLUEMonte Rosa Therapeutics Inc
26/04/202322h07Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:GLUEMonte Rosa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GLUE

Dernières Valeurs Consultées

IDCM
OMGBTC
OMG Network
NASDAQ
TWLVU
Twelve Seas Investment C...
BOV
BBASS437
BBASS437 Ex:21,34
GATE
KLIMAUSDT
Klima DAO
BIT
F08510
Vontobel Financial Produ...
COIN
XBPBTC
EU
C472T
C472T
BOV
CRVD5L
DON CAROLINA PNA PNA
EU
ALODC
OmerDecugis & Cie
EU
BPCHI
BPCE Sfh BPCESFH2.36%MAY28
BOV
KLBN3Q
KLABIN ON
EU
ALVET
TheraVet
EU
MLEAV
Eavs
EU
PAR
Paris Reality
EU
U982S
U982S
LSE
NBPE
Nb Private Equity Partners
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés